title: Vaccines in the treatment of invasive candidiasis.
abstract: Candida albicans is the most common cause of hematogenously disseminated candidiasis, and this disease is particularly prevalent in immunocompromised patients. The mortality of invasive candidiasis remains 40% to 50% even with the proper treatment with current antifungal drugs. Recently, with the better understanding of host-fungus interactions, notable progress has been made in antifungal vaccine research. Most antifungal vaccines exert protection by inducing either (or both) B-cell and T-cell responses. Here we summarize the current available information on C. albicans vaccines, highlight the obstacles that researchers identified, and offer several suggestions.
authors.affiliation: a Center for New Drug Research; School of Pharmacy ; Second Military Medical University ; 325 Guohe Road; Shanghai , P.R. China.
authors.forename: Xiao-juan
authors.initials: XJ
authors.lastname: Wang
authors.forename: Xue
authors.initials: X
authors.lastname: Sui
authors.forename: Lan
authors.initials: L
authors.lastname: Yan
authors.forename: Yan
authors.initials: Y
authors.lastname: Wang
authors.forename: Yong-bing
authors.initials: YB
authors.lastname: Cao
authors.forename: Yuan-ying
authors.initials: YY
authors.lastname: Jiang
mesh_terms: D000818:Animals; D002176:Candida albicans / Q000276:immunology* / Q000472:pathogenicity; D058365:Candidiasis, Invasive / Q000517:prevention & control*; D005657:Fungal Vaccines / Q000276:immunology; D006801:Humans; D007116:Immunization, Passive; D014613:Vaccines, Attenuated / Q000276:immunology; D018074:Vaccines, Conjugate; D022223:Vaccines, Subunit / Q000276:immunology
chemical_list: D005657:Fungal Vaccines; D014613:Vaccines, Attenuated; D018074:Vaccines, Conjugate; D022223:Vaccines, Subunit
keywords: Candida albicans; immune response; invasive candidiasis; vaccine; virulence